Author:
Couchman L.,Birch M.,Ireland R.,Corrigan A.,Wickramasinghe S.,Josephs D.,Spicer J.,Flanagan R. J.
Publisher
Springer Science and Business Media LLC
Subject
Biochemistry,Analytical Chemistry
Reference26 articles.
1. Kolibaba KS, Druker BJ (1997) Protein tyrosine kinases and cancer. Biochim Biophys Acta 1333:F217–F248
2. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493–502
3. BNF (2011) British national formulary, edition 62. BMJ Group/Pharmaceutical Press, London
4. Van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treatment Rev 35:692–706
5. Scheffler M, Di Gion P, Doroshyenko O, Wolf J, Fuhr U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines. Clin Pharmacokinet 50:371–403
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献